Professor Paul J Farrell

Publications


Journals

  • Tzartos JS; Khan G; Vossenkamper A; Cruz-Sadaba M; Lonardi S; Sefia E; Meager A; Elia A; et alMiddeldorp JM; Clemens M; Farrell PJ; Giovannoni G; Meier UC. (3 Jan 2012). Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 78:15-23. DOI.
  • Cancian L; Bosshard R; Lucchesi W; Karstegl CE; Farrell PJ. (Jul 2011). C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog. 7:e1002164. DOI.
  • Kouzarides T; Packham G; Cook A; Farrell PJ. (Feb 1991). The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene. 6:195-204.
  • Lai IY-C; Farrell PJ; Kellam P. (1 Feb 2011). X-box binding protein 1 induces the expression of the lytic cycle transactivator of Kaposi's sarcoma-associated herpesvirus but not Epstein Barr virus in co-infected primary effusion lymphoma. JOURNAL OF GENERAL VIROLOGY. 92:421-431. DOI.
  • Gregorovic G; Bosshard R; Karstegl CE; White RE; Pattle S; Chiang AK; Dittrich-Breiholz O; Kracht M; et alRuss R; Farrell PJ. (Apr 2011). Cellular gene expression that correlates with EBER expression in Epstein-Barr Virus-infected lymphoblastoid cell lines. J Virol. 85:3535-3545. DOI.
  • McDonald C; Karstegl CE; Kellam P; Farrell PJ. (Mar 2010). Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency. J Gen Virol. 91:622-629. DOI.
  • Brady G; Farrell PJ. (Nov 2009). RUNX3-mediated repression of RUNX1 in B cells. J Cell Physiol. 221:283-287. DOI.
  • Brady G; Whiteman HJ; Spender LC; Farrell PJ. (Jul 2009). Downregulation of RUNX1 by RUNX3 requires the RUNX3 VWRPY sequence and is essential for Epstein-Barr virus-driven B-cell proliferation. J Virol. 83:6909-6916. DOI.
  • McDonald CM; Petosa C; Farrell PJ. (Apr 2009). Interaction of Epstein-Barr virus BZLF1 C-terminal tail structure and core zipper is required for DNA replication but not for promoter transactivation. J Virol. 83:3397-3401. DOI.
  • Al-Mozaini M; Bodelon G; Karstegl CE; Jin B; Al-Ahdal M; Farrell PJ. (Feb 2009). Epstein-Barr virus BART gene expression. J Gen Virol. 90:307-316. DOI.
  • Lucchesi W; Brady G; Dittrich-Breiholz O; Kracht M; Russ R; Farrell PJ. (1 Aug 2008). Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. JOURNAL OF VIROLOGY. 82:7456-7466. Author weblink DOI.
  • Brady G; Macarthur GJ; Farrell PJ. (Jul 2008). Epstein-Barr virus and Burkitt lymphoma. Postgrad Med J. 84:372-377. DOI.
  • Brady G; MacArthur GJ; Farrell PJ. (Dec 2007). Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol. 60:1397-1402. DOI.
  • Farrell PJ. (Oct 2007). Role for HLA in susceptibility to infectious mononucleosis. J Clin Invest. 117:2756-2758. DOI.
  • Pattle SB; Farrell PJ. (Nov 2006). The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther. 6:1193-1205. DOI.
  • Spender LC; Lucchesi W; Bodelon G; Bilancio A; Karstegl CE; Asano T; Dittrich-Breiholz O; Kracht M; et alVanhaesebroeck B; Farrell PJ. (Oct 2006). Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p55alpha regulatory subunit of PI3-kinase and its role in survival of EREB2.5 cells. J Gen Virol. 87:2859-2867. DOI.
  • Amon W; White RE; Farrell PJ. (May 2006). Epstein-Barr virus origin of lytic replication mediates association of replicating episomes with promyelocytic leukaemia protein nuclear bodies and replication compartments. J Gen Virol. 87:1133-1137. DOI.
  • Whiteman HJ; Farrell PJ. (2006). RUNX expression and function in human B cells. Crit Rev Eukaryot Gene Expr. 16:31-44.
  • Syed N; Smith P; Sullivan A; Spender LC; Dyer M; Karran L; O'Nions J; Allday M; et alHoffmann I; Crawford D; Griffin B; Farrell PJ; Crook T. (1 Jan 2006). Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. BLOOD. 107:250-256. Author weblink DOI.
  • Amon W; Farrell PJ. (May 2005). Reactivation of Epstein-Barr virus from latency. Rev Med Virol. 15:149-156. DOI.
  • Spender LC; Whiteman HJ; Karstegl CE; Farrell PJ. (10 Mar 2005). Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells. Oncogene. 24:1873-1881. DOI.
  • Farrell PJ. (Jan 2005). Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?. Nat Clin Pract Oncol. 2:14-15. DOI.
  • Amon W; Binné UK; Bryant H; Jenkins PJ; Karstegl CE; Farrell PJ. (Dec 2004). Lytic cycle gene regulation of Epstein-Barr virus. J Virol. 78:13460-13469. DOI.
  • Sullivan A; Syed N; Gasco M; Bergamaschi D; Trigiante G; Attard M; Hiller L; Farrell PJ; et alSmith P; Lu X; Crook T. (22 Apr 2004). Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 23:3328-3337. DOI.
  • de Jesus O; Smith PR; Spender LC; Elgueta Karstegl C; Niller HH; Huang D; Farrell PJ. (Jun 2003). Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J Gen Virol. 84:1443-1450.
  • Bergamaschi D; Gasco M; Hiller L; Sullivan A; Syed N; Trigiante G; Yulug I; Merlano M; et alNumico G; Comino A; Attard M; Reelfs O; Gusterson B; Bell AK; Heath V; Tavassoli M; Farrell PJ; Smith P; Lu X; Crook T. (Apr 2003). p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 3:387-402.
  • Binné UK; Amon W; Farrell PJ. (Oct 2002). Promoter sequences required for reactivation of Epstein-Barr virus from latency. J Virol. 76:10282-10289.
  • Bryant H; Farrell PJ. (Oct 2002). Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency. J Virol. 76:10290-10298.
  • Farrell PJ. (1 Sep 2002). Tumour viruses - could they be an Achilles' heel of cancer?. EUROPEAN JOURNAL OF CANCER. 38:1815-1816. Author weblink DOI.
  • Farrell PJ. (1 Jun 2002). Cell-switching and kissing. NATURE MEDICINE. 8:559-560. Author weblink DOI.
  • Spender LC; Cornish GH; Sullivan A; Farrell PJ. (May 2002). Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol. 76:4919-4927.
  • Gasco M; Bell AK; Heath V; Sullivan A; Smith P; Hiller L; Yulug I; Numico G; et alMerlano M; Farrell PJ; Tavassoli M; Gusterson B; Crook T. (1 Apr 2002). Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res. 62:2072-2076.
  • Gasco M; Sullivan A; Repellin C; Brooks L; Farrell PJ; Tidy JA; Dunne B; Gusterson B; et alEvans DJ; Crook T. (14 Mar 2002). Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene. 21:1876-1881. DOI.
  • Reddy A; Yuille M; Sullivan A; Repellin C; Bell A; Tidy JA; Evans DJ; Farrell PJ; et alGusterson B; Gasco M; Crook T. (4 Mar 2002). Analysis of CHK2 in vulval neoplasia. Br J Cancer. 86:756-760. DOI.
  • Sullivan A; Yuille M; Repellin C; Reddy A; Reelfs O; Bell A; Dunne B; Gusterson BA; et alOsin P; Farrell PJ; Yulug I; Evans A; Ozcelik T; Gasco M; Crook T. (21 Feb 2002). Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene. 21:1316-1324. DOI.
  • Brooks LA; Sullivan A; O'Nions J; Bell A; Dunne B; Tidy JA; Evans DJ; Osin P; et alVousden KH; Gusterson B; Farrell PJ; Storey A; Gasco M; Sakai T; Crook T. (21 Jan 2002). E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia. Br J Cancer. 86:263-268. DOI.
  • O'Nions J; Brooks LA; Sullivan A; Bell A; Dunne B; Rozycka M; Reddy A; Tidy JA; et alEvans D; Farrell PJ; Evans A; Gasco M; Gusterson B; Crook T. (16 Nov 2001). p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer. 85:1551-1556. DOI.
  • Wensing B; Stühler A; Jenkins P; Hollyoake M; Karstegl CE; Farrell PJ. (Jul 2001). Variant chromatin structure of the oriP region of Epstein-Barr virus and regulation of EBER1 expression by upstream sequences and oriP. J Virol. 75:6235-6241. DOI.
  • Spender LC; Cornish GH; Rowland B; Kempkes B; Farrell PJ. (Apr 2001). Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J Virol. 75:3537-3546. DOI.
  • Inman GJ; Binné UK; Parker GA; Farrell PJ; Allday MJ. (Mar 2001). Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death. J Virol. 75:2400-2410. DOI.
  • Farrell PJ. (2001). Epstein-Barr virus. The B95-8 strain map. Methods Mol Biol. 174:3-12. DOI.
  • Brooks LA; Tidy JA; Gusterson B; Hiller L; O'Nions J; Gasco M; Marin MC; Farrell PJ; et alKaelin WG; Crook T. (15 Dec 2000). Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res. 60:6875-6877.
  • Smith PR; de Jesus O; Turner D; Hollyoake M; Karstegl CE; Griffin BE; Karran L; Wang Y; et alHayward SD; Farrell PJ. (Apr 2000). Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J Virol. 74:3082-3092.
  • Wensing B; Farrell PJ. (Jan 2000). Regulation of cell growth and death by Epstein-Barr virus. Microbes Infect. 2:77-84.
  • Jenkins PJ; Binné UK; Farrell PJ. (Jan 2000). Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol. 74:710-720.
  • Kiermaier A; Gawn JM; Desbarats L; Saffrich R; Ansorge W; Farrell PJ; Eilers M; Packham G. (2 Dec 1999). DNA binding of USF is required for specific E-box dependent gene activation in vivo. ONCOGENE. 18:7200-7211. Author weblink DOI.
  • Spender LC; Cannell EJ; Hollyoake M; Wensing B; Gawn JM; Brimmell M; Packham G; Farrell PJ. (Jun 1999). Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol. 73:4678-4688.
  • Cannell EJ; Farrell PJ; Sinclair AJ. (20 Nov 1998). Cell cycle arrest following exposure of EBV-immortalised B-cells to gamma irradiation correlates with inhibition of cdk2 activity. FEBS Lett. 439:297-301.
  • Farrell PJ. (May 1998). Signal transduction from the Epstein-Barr virus LMP-1 transforming protein. Trends Microbiol. 6:175-177.
  • Cludts I; Farrell PJ. (Mar 1998). Multiple functions within the Epstein-Barr virus EBNA-3A protein. J Virol. 72:1862-1869.
  • Radkov SA; Bain M; Farrell PJ; West M; Rowe M; Allday MJ. (Nov 1997). Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J Virol. 71:8552-8562.
  • Wangoo A; Shaw RJ; Diss TC; Farrell PJ; du Bois RM; Nicholson AG. (Oct 1997). Cryptogenic fibrosing alveolitis: lack of association with Epstein-Barr virus infection. Thorax. 52:888-891.
  • Farrell PJ; Hollyoake M; Niedobitek G; Agathanggelou A; Morgan A; Wedderburn N. (Jun 1997). Direct demonstration of persistent Epstein-Barr virus gene expression in peripheral blood of infected common marmosets and analysis of virus-infected tissues in vivo. J Gen Virol. 78 ( Pt 6):1417-1424.
  • Evans TJ; Brooks L; Farrell PJ. (Mar 1997). A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers. Gene Ther. 4:264-267. DOI.
  • Farrell PJ; Cludts I; Stühler A. (1997). Epstein-Barr virus genes and cancer cells. Biomed Pharmacother. 51:258-267.
  • Parker GA; Crook T; Bain M; Sara EA; Farrell PJ; Allday MJ. (19 Dec 1996). Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene. 13:2541-2549.
  • Cannell EJ; Farrell PJ; Sinclair AJ. (3 Oct 1996). Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells. Oncogene. 13:1413-1421.
  • Jenkins PJ; Farrell PJ. (1 Aug 1996). Are particular Epstein-Barr virus strains linked to disease?. SEMINARS IN CANCER BIOLOGY. 7:209-215. Author weblink DOI.
  • Bain M; Watson RJ; Farrell PJ; Allday MJ. (Apr 1996). Epstein-Barr virus nuclear antigen 3C is a powerful repressor of transcription when tethered to DNA. J Virol. 70:2481-2489.
  • Evans TJ; Farrell PJ; Swaminathan S. (Mar 1996). Molecular genetic analysis of Epstein-Barr virus Cp promoter function. J Virol. 70:1695-1705.
  • Allday MJ; Inman GJ; Crawford DH; Farrell PJ. (16 Oct 1995). DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. EMBO J. 14:4994-5005.
  • Inman GJ; Farrell PJ. (Sep 1995). Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. J Gen Virol. 76 ( Pt 9):2141-2149.
  • Sinclair AJ; Farrell PJ. (Sep 1995). Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol. 69:5461-5468.
  • Brooks L; Niedobitek G; Agathanggelou A; Farrell PJ. (May 1995). The expression of variant CD44 in nasopharyngeal carcinoma is unrelated to expression of LMP-1. Am J Pathol. 146:1102-1112.
  • Allday MJ; Sinclair A; Parker G; Crawford DH; Farrell PJ. (3 Apr 1995). Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO J. 14:1382-1391.
  • Farrell PJ. (Mar 1995). Epstein-Barr virus immortalizing genes. Trends Microbiol. 3:105-109.
  • Sinclair AJ; Palmero I; Holder A; Peters G; Farrell PJ. (Feb 1995). Expression of cyclin D2 in Epstein-Barr virus-positive Burkitt's lymphoma cell lines is related to methylation status of the gene. J Virol. 69:1292-1295.
  • Evans TJ; Jacquemin MG; Farrell PJ. (1 Feb 1995). Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology. 206:866-877. DOI.
  • Horner D; Lewis M; Farrell PJ. (1995). Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV-related cancers. Intervirology. 38:195-205.
  • Cook ID; Shanahan F; Farrell PJ. (15 Nov 1994). Epstein-Barr virus SM protein. Virology. 205:217-227. DOI.
  • Sinclair AJ; Palmero I; Peters G; Farrell PJ. (15 Jul 1994). EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:3321-3328.
  • Vousden KH; Farrell PJ. (Jul 1994). Viruses and human cancer. Br Med Bull. 50:560-581.
  • Allday MJ; Farrell PJ. (Jun 1994). Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol. 68:3491-3498.
  • Sinclair AJ; Jacquemin MG; Brooks L; Shanahan F; Brimmell M; Rowe M; Farrell PJ. (Mar 1994). Reduced signal transduction through glucocorticoid receptor in Burkitt's lymphoma cell lines. Virology. 199:339-353. DOI.
  • Lau R; Middeldorp J; Farrell PJ. (Aug 1993). Epstein-Barr virus gene expression in oral hairy leukoplakia. Virology. 195:463-474. DOI.
  • Vousden KH; Crook T; Farrell PJ. (May 1993). Biological activities of p53 mutants in Burkitt's lymphoma cells. J Gen Virol. 74 ( Pt 5):803-810.
  • Packham G; Brimmell M; Cook D; Sinclair AJ; Farrell PJ. (Feb 1993). Strain variation in Epstein-Barr virus immediate early genes. Virology. 192:541-550. DOI.
  • Lau R; Packham G; Farrell PJ. (Oct 1992). Differential splicing of Epstein-Barr virus immediate-early RNA. J Virol. 66:6233-6236.
  • Sinclair AJ; Farrell PJ. (Aug 1992). Epstein-Barr virus transcription factors. Cell Growth Differ. 3:557-563.
  • Allan GJ; Inman GJ; Parker BD; Rowe DT; Farrell PJ. (Jun 1992). Cell growth effects of Epstein-Barr virus leader protein. J Gen Virol. 73 ( Pt 6):1547-1551.
  • Sinclair AJ; Brimmell M; Farrell PJ. (Jan 1992). Reciprocal antagonism of steroid hormones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression. J Virol. 66:70-77.
  • Farrell PJ; Allan GJ; Shanahan F; Vousden KH; Crook T. (Oct 1991). p53 is frequently mutated in Burkitt's lymphoma cell lines. EMBO J. 10:2879-2887.
  • Sinclair AJ; Brimmell M; Shanahan F; Farrell PJ. (May 1991). Pathways of activation of the Epstein-Barr virus productive cycle. J Virol. 65:2237-2244.
  • Parker BD; Bankier A; Satchwell S; Barrell B; Farrell PJ. (Nov 1990). Sequence and transcription of Raji Epstein-Barr virus DNA spanning the B95-8 deletion region. Virology. 179:339-346.
  • Packham G; Economou A; Rooney CM; Rowe DT; Farrell PJ. (May 1990). Structure and function of the Epstein-Barr virus BZLF1 protein. J Virol. 64:2110-2116.
  • Laux G; Economou A; Farrell PJ. (Nov 1989). The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol. 70 ( Pt 11):3079-3084.
  • Tidy JA; Mason WP; Farrell PJ. (Sep 1989). A new and sensitive method of screening for human papillomavirus infection. Obstet Gynecol. 74:410-414.
  • Rooney CM; Rowe DT; Ragot T; Farrell PJ. (Jul 1989). The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol. 63:3109-3116.
  • Tidy JA; Vousden KH; Farrell PJ. (3 Jun 1989). Relation between infection with a subtype of HPV16 and cervical neoplasia. Lancet. 1:1225-1227.
  • Tidy J; Vousden KH; Mason P; Farrell PJ. (Apr 1989). A novel deletion within the upstream regulatory region of episomal human papillomavirus type 16. J Gen Virol. 70 ( Pt 4):999-1004.
  • Cunningham D; Hickish T; Rosin RD; Sauven P; Baron JH; Farrell PJ; Isaacson P. (1 Apr 1989). Polymerase chain reaction for detection of dissemination in gastric lymphoma. Lancet. 1:695-697.
  • TIDY JA; PARRY GCN; WARD P; COLEMAN DV; PETO J; MALCOLM ADB; FARRELL PJ. (25 Feb 1989). HIGH-RATE OF HUMAN PAPILLOMAVIRUS TYPE-16 INFECTION IN CYTOLOGICALLY NORMAL CERVICES. LANCET. 1:434-434. Author weblink.
  • Farrell PJ; Rowe DT; Rooney CM; Kouzarides T. (Jan 1989). Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 8:127-132.
  • Laux G; Perricaudet M; Farrell PJ. (Mar 1988). A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J. 7:769-774.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook